Published in Women's Health Weekly, October 20th, 2005
Arimidex is the only aromatase inhibitor with study results representing a full 5 years of efficacy and safety data in this primary adjuvant setting, and is now the only aromatase inhibitor that has proven superior disease-free survival over tamoxifen in the primary adjuvant setting.
This long-term data for Arimidex provides clinicians and patients an opportunity to make the most informed decision about their primary...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly